CareDx: Q3 Earnings Snapshot
CareDx Inc. (CDNA) reported Q3 net income of $19.3M, or 35 cents per share, with adjusted EPS of 70 cents. Revenue was $139.4M. The company expects full-year revenue between $520M and $530M, according to its earnings release.
How this was made
The 30-second read
Why it matters
The combination of reported Q3 revenue/EPS and a specific full-year revenue range can shift near-term estimates and risk appetite for the name.
Market read
Company-specific earnings and guidance are actionable for traders adjusting models and expectations for CDNA.
What to watch
Traders may focus more on adjusted EPS quality, margin trajectory, and any commentary on test volumes or pipeline, none of which is detailed in the provided text.
Background
CareDx is a molecular diagnostics company; this article summarizes its Q3 financial results and full-year revenue outlook.
Ticker impact
CareDx reported Q3 net income of $19.3M, revenue of $139.4M, and guided full-year revenue to $520M-$530M.
Likely modest repricing as traders compare the reported Q3 results and the $520M-$530M full-year revenue range against prevailing expectations.
The article contains a first-reported quarterly earnings snapshot and a specific revenue guidance range, but it lacks consensus/beat-miss context or a same-day stock move.
Market effects
Provides a datapoint for the molecular diagnostics/clinical diagnostics peer group on demand and revenue trajectory.
Limited, as the company is US-listed and the release is company-specific.
Low, as there is no cross-border policy, supply-chain, or macro linkage described.
Counterpoint
If the guidance range is broadly in line with expectations, the earnings snapshot may not change positioning much beyond short-term noise.
Key entities
- companyCareDx Inc.
Reported Q3 net income of $19.3M, revenue of $139.4M, and guided full-year revenue to $520M-$530M.
